In Vitro Immunological Effects of CXCR3 Inhibitor AMG487 on Dendritic Cells
- 1 April 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 68 (2), 1-9
- https://doi.org/10.1007/s00005-020-00577-3
Abstract
AMG 487 is the targeted blocker of chemokine receptor CXCR3 and improves inflammatory symptoms by blocking the inflammatory cycle. Here we investigated whether AMG 487 affects dendritic cell (DC) biology and function. The expression of co-stimulatory markers on DCs was reduced, indicating the semi-mature state of DC when AMG 487 was added throughout the in vitro differentiation period. Additionally, when added solely during the final lipopolysaccharide-induced activation step, AMG 487 inhibited DC activation, as demonstrated by a decreased expression of activation markers. AMG487 also promoted the expression of PD-L2 and impaired the ability to induce antigen-specific T cell responses. Our results demonstrated that AMG 487 significantly affects DC maturity in vitro and function leading to impaired T cell activation, inducing DCs to have characteristics similar to tolerogenic DCs. AMG 487 may directly play an immunomodulatory role during DC development and functional shaping.Keywords
Funding Information
- National Natural Science Foundation of China (81570160, 8197160)
This publication has 38 references indexed in Scilit:
- IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction — A comparative study of human clinical-applicable DCClinical Immunology, 2012
- Tolerogenic dendritic cells and their role in transplantationSeminars in Immunology, 2011
- Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3Blood, 2011
- Tolerogenic dendritic cells and their potential applicationsImmunology, 2011
- Negative vaccination by tolerogenic dendritic cells in organ transplantationCurrent Opinion in Organ Transplantation, 2010
- Carbon Monoxide Inhibits TLR-Induced Dendritic Cell ImmunogenicityThe Journal of Immunology, 2009
- An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple DosingDrug Metabolism and Disposition, 2008
- Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cellsJournal of Leukocyte Biology, 2007
- Dendritic cells: emerging pharmacological targets of immunosuppressive drugsNature Reviews Immunology, 2004
- The B7–CD28 superfamilyNature Reviews Immunology, 2002